These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 23552512

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Modulation of the antioxidant defence in different developmental stages of Schistosoma mansoni by praziquantel and artemether.
    El-Bassiouni EA, Helmy MH, Saad EI, El-Nabi Kamel MA, Abdel-Meguid E, Hussein HS.
    Br J Biomed Sci; 2007; 64(4):168-74. PubMed ID: 18236739
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Schistosomiasis: challenges for control, treatment and drug resistance.
    Fenwick A, Webster JP.
    Curr Opin Infect Dis; 2006 Dec; 19(6):577-82. PubMed ID: 17075334
    [Abstract] [Full Text] [Related]

  • 27. Detection of praziquantel resistance in schistosomes.
    Liang YS, Coles GC, Doenhoff MJ.
    Trop Med Int Health; 2000 Jan; 5(1):72. PubMed ID: 10672208
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Toward organometallic antischistosomal drug candidates.
    Hess J, Keiser J, Gasser G.
    Future Med Chem; 2015 Jan; 7(6):821-30. PubMed ID: 25996072
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Recent Advances in the Synthesis of Antischistosomal Drugs and Agents.
    Liu LX, Li-Li J, Qiong C, Xiao-Lin F.
    Mini Rev Med Chem; 2017 Jan; 17(5):467-484. PubMed ID: 24251801
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. THE SUSCEPTIBILITY OF RECENT ISOLATES OF Schistosoma mansoni TO PRAZIQUANTEL.
    Mendonça AM, Feitosa AP, Veras DL, Matos-Rocha TJ, Cavalcanti MG, Barbosa CC, Brayner FA, Alves LC.
    Rev Inst Med Trop Sao Paulo; 2016 Jan; 58():7. PubMed ID: 26910445
    [Abstract] [Full Text] [Related]

  • 36. [Histone deacetylase and histone acetyltransferase inhibitors as antischistosomal agents: a review].
    Wang Y, Xu J, Xia C.
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2024 Mar 25; 36(2):207-214. PubMed ID: 38857968
    [Abstract] [Full Text] [Related]

  • 37. Chemotherapy for Fighting Schistosomiasis: Past, Present and Future.
    Mäder P, Rennar GA, Ventura AMP, Grevelding CG, Schlitzer M.
    ChemMedChem; 2018 Nov 20; 13(22):2374-2389. PubMed ID: 30212614
    [Abstract] [Full Text] [Related]

  • 38. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers.
    Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, Day TA, Bennett JL.
    Am J Trop Med Hyg; 1999 Jun 20; 60(6):932-5. PubMed ID: 10403323
    [Abstract] [Full Text] [Related]

  • 39. Schistosomiasis therapeutics: whats in the pipeline?
    Trainor-Moss S, Mutapi F.
    Expert Rev Clin Pharmacol; 2016 Jun 20; 9(2):157-60. PubMed ID: 26508363
    [Abstract] [Full Text] [Related]

  • 40. Could we expect new praziquantel derivatives? A meta pharmacometrics/pharmacoinformatics analysis of all antischistosomal praziquantel derivatives found in the literature.
    da Silva VBR, Boucherle B, El-Methni J, Hoffmann B, da Silva AL, Fortune A, de Lima MDCA, Thomas A.
    SAR QSAR Environ Res; 2019 Jun 20; 30(6):383-401. PubMed ID: 31144535
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.